i been trying to figure out plausible explanations for SP weakness recently - had a light bulb moment today. SP decline correlates well with the increased US covid deaths staring early Nov.
On face value - COVID seems to killing the target patient group for wet AMD ie. the elderly.
By the end of pandemic, I expect around 500-600k deaths in the US alone with probably decent % (maybe 15-20%) of those may have wAMD. So that’s a reduction of the over total 1M wAMD US patients by 50-100k or 5-10% hence the market may be discounting lower revenues for all players.
Phase 3 Trials, page-48
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
61.5¢ |
Change
0.005(0.82%) |
Mkt cap ! $757.1M | |||
| Open | High | Low | Value | Volume |
| 61.0¢ | 62.5¢ | 59.0¢ | $953.6K | 1.560M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 22662 | 61.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 61.5¢ | 24454 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| OPT (ASX) Chart |